Friday, October 25, 2019

In the News: $260 Million Settlement Announced in Opioid Epidemic Case

Center on Addiction
Partnership for Drug-Free Kids
Top Drug & Alcohol News of the Week
hands pills
Featured News: Analysis of Drug Tests Finds Frequent Misuse of Opioids and Other Controlled Drugs
Prescription drug misuse continues to be a serious problem in the United States, according to a new report by Quest Diagnostics. Read More
money and pills
$260 Million Settlement Announced in Opioid Epidemic Case
Four drug companies and two Ohio counties have reached a $260 million settlement in a landmark lawsuit over the opioid epidemic, The Washington Post reports. Read More
juul e-cigarette and e-liquids
Juul Suspends Sales of Mango, Creme, Fruit and Cucumber Flavored Products
E-cigarette maker Juul Labs says it will suspend sales of its mango, crème, fruit and cucumber flavored products. Read More
Help Us Continue to Empower Families:

FDA Authorizes Marketing of “Reduced Risk” Smokeless Tobacco Products
The U.S. Food and Drug Administration has for the first time authorized the marketing of “reduced risk” tobacco products. The agency said eight smokeless tobacco products are less harmful than cigarettes. Read More
Study Shows Flavors Entice Teens to Try—and Stick With—Vaping
Teens who first try flavored e-cigarettes, cigar or smokeless tobacco are much more likely to still be using that product a year later, compared with those who try a non-flavored product, a new study finds. Read More
New Vaping Cessation Programs Aim to Help Teens Quit E-Cigarettes
National Jewish Health, a hospital in Denver, this summer launched a vaping cessation program aimed at teens. The program includes coaching by text, NPR reports. Read More
Other Headlines of Interest
Partnership for Drug-Free Kids and Center on Addiction have merged. Learn More



Center on Addiction  Partnership for Drug-Free Kids
Facebook  Twitter  YouTube  Instagram  LinkedIn
© Partnership for Drug-Free Kids
Center on Addiction
633 Third Ave | 19th Floor
New York, NY 10017-6706
Privacy Policy 

No comments:

Post a Comment